Bullous Pemphigoid - Acute Flare and ED Management

Key Points

• Tense pruritic bullae in an older adult strongly suggest bullous pemphigoid.
• Use two biopsies when possible: lesional skin for histology and perilesional skin for direct immunofluorescence.
• High-potency topical corticosteroids are effective and can reduce systemic steroid exposure.
• Systemic therapy is used for extensive or severe disease and should be individualized for an often frail population.
• Review medications for potential triggers or associations.
• Treat secondary bacterial infection when present and protect denuded skin with nonadherent wound care.

Algorithm

1. Recognize tense bullae and assess mucosal disease, skin pain, systemic toxicity, and drug exposure.
2. Obtain lesional biopsy for histology and perilesional biopsy for direct immunofluorescence.
3. Use high-potency topical corticosteroid therapy when disease extent and caregiving allow.
4. Escalate to systemic or steroid-sparing therapy with dermatology for extensive or refractory disease.
5. Provide wound care, pain control, and infection surveillance.
6. Admit when skin failure, infection, dehydration, or care needs exceed outpatient capability.

Clinical Synopsis & Reasoning

Bullous pemphigoid most often affects older adults and begins with intense pruritus, urticarial or eczematous plaques, followed by tense fluid-filled blisters that resist rupture because the split is beneath the epidermis. Mucosal disease is less prominent than in pemphigus vulgaris. The differential includes bullous drug eruption, epidermolysis bullosa acquisita, linear IgA disease, dermatitis herpetiformis, edema bullae, bullous diabeticorum, porphyria cutanea tarda, and severe cutaneous adverse reactions.

Diagnosis requires clinicopathologic correlation. A biopsy from the edge of a fresh blister is used for routine histology, while a separate perilesional normal-appearing skin biopsy is submitted for direct immunofluorescence. Linear IgG and C3 along the basement membrane supports bullous pemphigoid. Serum BP180 and BP230 antibodies can support diagnosis and sometimes reflect disease activity, but they do not replace appropriate biopsy when the diagnosis is uncertain.

Medication review is important. DPP-4 inhibitors and several immune therapies have recognized associations, although causality must be individualized. Extensive denuded skin can lead to pain, infection, fluid loss, and functional decline even though bullae are often less superficially fragile than pemphigus. Fever or purulence warrants evaluation for secondary infection rather than assumption that inflammation alone explains systemic findings.

Treatment Strategy & Disposition

High-potency topical corticosteroids can control even fairly extensive bullous pemphigoid and may reduce systemic adverse effects when adequate caregiver support makes whole-body application feasible. Limited disease can often be managed with potent topical therapy to active areas. More extensive, rapidly progressive, or function-limiting disease may require systemic prednisone or a steroid-sparing strategy under dermatology supervision.

Steroid-sparing options include doxycycline-based regimens, immunosuppressants, and targeted biologic therapy in selected patients. Choice depends on frailty, infection risk, diabetes, renal and hepatic function, malignancy, and access to specialist care. Because patients are often elderly, the harms of prolonged systemic glucocorticoids can be substantial and should be actively minimized.

Use nonadherent dressings for ruptured bullae, preserve intact blister roofs when practical, and monitor for cellulitis or sepsis. Admit patients with extensive skin failure, uncontrolled pain, serious infection, severe dehydration, inability to manage wound care, or major comorbidity destabilization. Arrange dermatology follow-up promptly for confirmation and a long-term steroid-sparing plan.

Epidemiology / Risk Factors

• Bullous pemphigoid is the most common autoimmune blistering disease in older adults.
• Incidence increases markedly with age and neurologic comorbidity is frequently reported.
• Several medications, including DPP-4 inhibitors, have been associated with disease onset.
• The condition is chronic-relapsing but can eventually remit.

Investigations

When to admit

Pharmacology

Prognosis / Complications

• Disease can be controlled in most patients but treatment toxicity is an important contributor to morbidity.
• Frailty, infection, and systemic glucocorticoid complications influence mortality more than the blisters alone.
• Relapses are common during treatment taper.
• Long-term management aims to suppress new blister formation while minimizing immunosuppression.

Patient Education / Counseling

• Explain that the blisters are autoimmune rather than contagious.
• Use gentle wound care and avoid adhesive trauma to fragile surrounding skin.
• Review warning signs of infection including fever, increasing redness, purulent drainage, or confusion.
• Discuss medication risks and the importance of dermatology follow-up for steroid-sparing treatment when needed.

Notes

The physical quality of the blister is useful. Bullous pemphigoid produces tense bullae because the epidermal roof remains relatively intact, whereas pemphigus produces much more fragile superficial blisters and erosions.

Treatment must account for age. A regimen that suppresses disease quickly but produces infection, delirium, severe hyperglycemia, or fractures may be a poor tradeoff in a frail patient. Topical and steroid-sparing strategies can therefore be especially valuable.

Wound burden should be estimated explicitly because it influences whether topical treatment is practical. Whole-body superpotent topical corticosteroid regimens can be very effective, but they require caregiver capacity, large medication quantities, and monitoring for systemic absorption. In a frail patient living alone, a theoretically safer topical regimen may be less realistic than a carefully supervised systemic plan. Conversely, an older patient with diabetes, recurrent infection, osteoporosis, or delirium risk may be harmed substantially by prolonged prednisone. The best regimen therefore balances blister control, treatment logistics, and comorbidity rather than treating systemic corticosteroids as the automatic default for widespread disease.

References

1. American Academy of Dermatology clinical resources — Link
2. European Academy of Dermatology and Venereology resources on autoimmune blistering disease — Link